Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jan;32(1):e16578.
doi: 10.1111/ene.16578.

A common marker of affect recognition dysfunction in the FTD spectrum of disorders

Affiliations

A common marker of affect recognition dysfunction in the FTD spectrum of disorders

Elisa Canu et al. Eur J Neurol. 2025 Jan.

Abstract

Background: Poor affect recognition is an early sign of frontotemporal dementia (FTD). Here, we applied the abbreviated version of the Comprehensive Affect Testing System (CATS-A) battery to Italian FTD cases and healthy controls (HC) to provide cut-offs of emotional dysfunction in the whole group and in different FTD clinical syndromes.

Methods: One hundred thirty-nine FTD patients (60 behavioural variant [bvFTD],13 semantic behavioural variant of FTD [sbvFTD], 28 progressive supranuclear palsy [PSP], 21 semantic [svPPA] and 17 nonfluent [nfvPPA] variants of primary progressive aphasia) and 116 HC were administered the CATS-A, yielding an Affective Recognition Quotient (ARQ), which was used as outcome measure. Age- and education-adjusted, regression-based norms were derived in HC. In patients, the ARQ was assessed for its internal reliability, factorial validity and construct validity by testing its association with another social cognition paradigm, the Story-Based Empath Task (SET). The diagnostic accuracy of the ARQ in discriminating patients from HC, genetic cases from HC and patient groups among each other was tested via ROC analyses.

Results: In the whole FTD cohort, CATS-A proved to be underpinned by a mono-component factor (51.1%) and was internally consistent (McDonald's ω = 0.76). Moreover, the ARQ converged with the SET (r(122) = 0.50; p < 0.001) and optimally discriminated HC from both the whole cohort (AUC = 0.89) and each clinical syndrome (AUC range: 0.83-0.92). Conversely, CATS-A subtests were able to distinguish patient groups.

Conclusions: The ARQ score from the CATS-A distinguishes FTD clinical syndromes from HC with high accuracy, making it an excellent tool for immediate use in clinical practice.

Keywords: CATS‐A; FTD; comprehensive affect testing system; emotion recognition; frontotemporal degeneration.

PubMed Disclaimer

Conflict of interest statement

E. Canu has received research supports from the Italian Ministry of Health. F. Verde is an associate editor for Journal of Alzheimer's Disease. N. Ticozzi received compensation for consulting services from Amylyx Pharmaceuticals and Zambon Biotech SA, and he is an associate editor for Frontiers in Aging Neuroscience. V. Silani received compensation for consulting services and/or speaking activities from AveXis, Cytokinetics, Italfarmaco, Liquidweb S.r.l., Novartis Pharma AG, Amylyx Pharmaceuticals, Biogen and Zambon Biotech SA, he receives or has received research supports from the Italian Ministry of Health, AriSLA and E‐Rare Joint Transnational Call, and he is in the Editorial Board of Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, European Neurology, American Journal of Neurodegenerative Diseases, Frontiers in Neurology, and Exploration of Neuroprotective Therapy. B. Poletti received compensation for consulting services and/or speaking activities from Liquidweb S.r.l, and she is an associate editor for Frontiers in Neuroscience. M. Filippi is Editor‐in‐Chief of the Journal of Neurology and an associate editor of Human Brain Mapping, Neurological Sciences, and Radiology; he received compensation for consulting services from Alexion, Almirall, Biogen, Merck, Novartis, Roche, Sanofi, speaking activities from Bayer, Biogen, Celgene, Chiesi Italia SpA, Eli Lilly, Genzyme, Janssen, Merck‐Serono, Neopharmed Gentili, Novartis, Novo Nordisk, Roche, Sanofi, Takeda and TEVA, participated in Advisory Boards for Alexion, Biogen, Bristol‐Myers Squibb, Merck, Novartis, Roche, Sanofi, Sanofi‐Aventis, Sanofi‐Genzyme and Takeda, and done scientific direction of educational events for Biogen, Merck, Roche, Celgene, Bristol‐Myers Squibb, Lilly, Novartis and Sanofi‐Genzyme; he receives research support from Biogen Idec, Merck‐Serono, Novartis, Roche, the Italian Ministry of Health, the Italian Ministry of University and Research and Fondazione Italiana Sclerosi Multipla. F. Agosta is an associate editor of NeuroImage: Clinical, has received speaker honoraria from Biogen Idec, Italfarmaco, Roche, Zambon and Eli Lilly, and received or has received research supports from the Italian Ministry of Health, the Italian Ministry of University and Research, AriSLA (Fondazione Italiana di Ricerca per la SLA), the European Research Council, the EU Joint Programme—Neurodegenerative Disease Research (JPND) and Foundation Research on Alzheimer Disease (France). V. Castelnovo, E.N. Aiello, G. de Luca, E. Sibilla, F. Freri, C. Tripodi, E.G. Spinelli, G. Cecchetti, G. Magnani, F. Caso, P. Caroppo, S. Prioni, C. Villa, L. Tremolizzo, I. Appollonio, V. Sturm, K.P. Rankin and M.L. Gorno‐Tempini have nothing to disclose.

Figures

FIGURE 1
FIGURE 1
Disease‐specific cut‐offs for the CATS‐A ARQ. Colours represent the different clinical phenotypes. Happy faces (smile and open eyes) reflect a ‘good’ diagnostic performance (SUI≥1.28); content faces (smile and closed eyes) reflect an ‘adequate’ diagnostic performance (SUI≥0.98). Figure created with BioRender.com. ARQ, affect recognition quotient; bvFTD, behavioural variant of frontotemporal dementia; CATS‐A, Abbreviated version of Comprehensive Affect Test System; FTD, frontotemporal dementia; g‐bvFTD, patients with behavioural variant of frontotemporal dementia carrying genetic mutations; g‐FTD, patients with frontotemporal degeneration carrying genetic mutations; nfvPPA, nonfluent variant of primary progressive aphasia; sbvFTD, semantic behavioural variant of frontotemporal dementia; svPPA, semantic variant of primary progressive aphasia; PSP, progressive supranuclear palsy; SUI, Summary Utility Index.

Similar articles

References

    1. Magno MA, Canu E, Agosta F, Filippi M. Measuring social cognition in frontotemporal lobar degeneration: a clinical approach. J Neurol. 2022;269:2227‐2244. - PubMed
    1. Haxby JV, Hoffman EA, Gobbini MI. The distributed human neural system for face perception. Trends Cogn Sci. 2000;4:223‐233. - PubMed
    1. Morton J, Johnson MH. CONSPEC and CONLERN: a two‐process theory of infant face recognition. Psychol Rev. 1991;98:164‐181. - PubMed
    1. Ekman P, Friesen WV. Constants across cultures in the face and emotion. J Pers Soc Psychol. 1971;17:124‐129. - PubMed
    1. Delbeuck X, Pollet M, Pasquier F, Bombois S, Moroni C. The clinical value of the faux pas test for diagnosing behavioral‐variant frontotemporal dementia. J Geriatr Psychiatry Neurol. 2022;35:62‐65. - PubMed